ProMIS Neurosciences Inc reports results for the quarter ended June 30 - Earnings Summary
ProMIS Neurosciences Inc reports results for the quarter ended June 30 - Earnings Summary
ProMIS Neurosciences Inc PMN.OQ reported a quarterly adjusted loss of $1.28 per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-7.25. The mean expectation of seven analysts for the quarter was for a loss of $1.38 per share. Wall Street expected results to range from $-2.09 to $-1.01 per share.
Reported revenue was zero; analysts expected zero.
ProMIS Neurosciences Inc's reported EPS for the quarter was a loss of $1.28.
The company reported a quarterly loss of $11.73 million.
ProMIS Neurosciences Inc shares had risen by 10.2% this quarter and gained 112.5% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 2% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for ProMIS Neurosciences Inc is $35.00, about 58.6% above its last closing price of $14.50
This summary was machine generated from LSEG data August 13 at 08:53 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -1.38 | -1.28 | Beat |
Mar. 31 2026 | -1.48 | -1.26 | Beat |
Dec. 31 2025 | -4.88 | -6.57 | Missed |
Sep. 30 2025 | -6.08 | -6.00 | Beat |